Viking Therapeutics (VKTX) could be the next big moneymaker with obesity drugs.

As we noted on March 14, “Keep an eye on Viking Therapeutics (VKTX) again,” we said on March 14. The first time we mentioned VKTX here, it traded at around $36.20. Weeks later, it would rally to about $100 on obesity drug trial data. Now, after pulling back on a competitor’s obesity trial data, it appears the stock is bottoming out. Last trading at $67.10, we’d like to see it make another run to nearly $100.”

To see a super simple way to predict market direction, click here.

Today, the VKTX stock is back to $76.45. From here, we’d like to see it closer to $100 again.

Earlier this year, the company reported that the injectable form of its obesity treatment helped patients lose up to 13.1% of their weight after 13 weeks. Then, the company said the tablet form of its treatment led to a weight loss of about 3.3% after 28 days in Phase 1 trials. That tablet form of the treatment is expected to enter Phase 2 trials in the second half of the year.


Ian Cooper